📋 Tender Overview
Personalized Prevention For Coronary Heart Disease
Personalised Medicine For Coronary Heart Disease Comes Of Agepersonalised Medicine (Tailoring Prevention Or Intervention To Individual Patients~ Medical Histories, Conditions And Circumstances) Seems Like A No-Brainer. Every Person Is Unique And Has A Specific Health Profile, A Complicated Combination Of Heredity, Environment And Lifestyle. Although Physicians And Scientists Have Been Working For Years Toward Personalised Medicine, Only Recently Has It Become A Real Possibility, With Advances In Fields Like Genomics, Data And Informatics, And Wearable Technology. Working To Prevent Morbidity And Mortality Associated With Coronary Heart Disease (Chd), The Eu-Funded Coroprevention Project Is Developing A Personalised Secondary Prevention Programme For Patients With Established Chd. The Health, Economic And Social Benefits Of The Methods Will Be Rigorously Evaluated Along With The Health Economics, To Improve Treatment Guidelines For The Benefit Of Patients And Healthcare Systems.
Funded Under
Societal Challenges - Health, Demographic Change And Well-Being
Total Cost
€ 22 641 162,04
Eu Contribution
€ 19 970 827,26
Coordinated By
Tampereen Korkeakoulusaatio Sr
Finland
Start Date
1 January 2020
End Date
31 December 2026
Objective
European Coronary Heart Disease (CHD) burden is unsustainable. Better risk stratification tools and personalized care of patients are needed for reducing morbidity and mortality of CHD and the associated economic burden. To this end we have planned to shape and implement a personalized secondary prevention program for patients with established CHD. This precision strategy will be tested in a prospective trial, the CoroPrevention Trial, a central element of our proposal. We aim to significantly reduce the numbers of coronary events by using outcome risk- and patient characteristics- guided prevention in CHD patients.
1. Prospectively evaluate clinical utility of personalized prevention in CHD
2. Evaluate health economic and social benefits of the personalized prevention in CHD
3. Discover predictive markers of drug treatment response in CHD
4. Improve current ESC guidelines based on RCT validated clinical data
5. Disseminate the refined prevention program to the attention of practitioners, patients, health care payers and policy makers
This program will establish a new economically sustainable personalized treatment practice applicable throughout Europe particularly to those regions where CHD prevention needs upgrading. The used protocols and technologies will carefully assessed by NICE using their standard evaluation methods that will allow independent expert opinions for different European authorities and decision makers. These opinion statements will further be supported by full Health Economics analyses of CoroPrevention Trial.
